


ETCTN Trials by Disease/Treatment Area: Solid Tumors- Dose Escalation Only (Disease-Specific Expansion)



NOTE: ▼ Limited trial; not open ETCTN-wide

**ETCTN Solid Tumors- Dose Escalation Only (Disease-Specific Expansion)  
Trials (Open as of 3/10/2026)**

<b>Protocol Number</b>	<b>Phase</b>	<b>Protocol Title</b>
<b>10358</b>	I/Ib	Phase 1/1B Study of DS-8201a in Combination with ATR Inhibition (AZD6738) in Advanced Solid Tumors with HER2 Expression (DASH Trial)
<b>10355</b>	I	A phase I study of DS-8201a in combination with olaparib in HER2-expressing malignancies
<b>10509</b>	I	A Phase 1 Study of BET Bromodomain Inhibitor ZEN003694 in Combination with the CDK4/6 Inhibitor Abemaciclib in Patients with NUT Carcinoma and Other Solid Tumors
<b>10579</b>	I	Phase I Trial of ZEN003694 (ZEN-3694) in Combination with Capecitabine in Patients with Solid Tumors
<b>10554</b>	I	Phase 1 Study of Trastuzumab Deruxtecan (DS-8201a) in Combination with Azenosertib (ZN-c3) in HER2-Expressing/Amplified Cyclin E-Amplified Gastric/Gastroesophageal Junction Cancer and Other Solid Tumors with HER2 Expression